Deciphera Pharmaceuticals, Inc.
DCPHNASDAQHealthcare
$25.59
+$0.02(+0.08%)
Market Cap$2.2B
P/E Ratio—
52W High$25.61
52W Low$9.9
Deciphera Pharmaceuticals, Inc. (DCPH) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · DCPH · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.16B | $0.13B | $0.10B | $0.04B | $0.03B |
| Cost of Revenue | $0.00B | $0.01B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.16B | $0.13B | $0.09B | $0.04B | $0.02B |
| Gross Margin %(computed) | 97.72% | 93.46% | 96.95% | 99.47% | 96.68% |
| Operating Expenses | |||||
| R&D Expenses | $0.23B | $0.19B | $0.26B | $0.20B | $0.16B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.37B | $0.31B | $0.39B | $0.31B | $0.23B |
| Operating Income | ($0.21B) | ($0.18B) | ($0.30B) | ($0.27B) | ($0.20B) |
| Operating Margin %(computed) | -129.14% | -136.32% | -312.10% | -644.36% | -802.90% |
| Interest Income | $0.02B | $0.00B | $0.00B | $0.00B | $0.01B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.19B) | ($0.18B) | ($0.30B) | ($0.27B) | ($0.19B) |
| Income Tax Expense | $0.00B | $0.00B | ($0.00B) | $0.00B | ($0.00B) |
| Net Income | ($0.19B) | ($0.18B) | ($0.30B) | ($0.27B) | ($0.19B) |
| Net Margin %(computed) | -119.34% | -133.49% | -308.73% | -633.19% | -765.97% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.29 | $-2.37 | $-5.11 | $-4.78 | $-4.47 |
| Wtd Avg Shares | 0.09B | 0.08B | 0.06B | 0.06B | 0.04B |
| EBITDA | ($0.21B) | ($0.17B) | ($0.30B) | ($0.26B) | ($0.18B) |
| EBITDA Margin %(computed) | -127.85% | -127.39% | -308.96% | -627.71% | -734.61% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Deciphera Pharmaceuticals, Inc. data
About Deciphera Pharmaceuticals, Inc. (DCPH) Income Statement
Deciphera Pharmaceuticals, Inc. (DCPH) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, DCPH reported revenue of $0.16B, gross profit of $0.16B (gross margin 97.72%), and net income of ($0.19B) — a net profit margin of -119.34%.
Frequently asked questions
DCPH · 4 questionsDeciphera Pharmaceuticals, Inc. (DCPH) reported revenue of $0.16B for 2023, up 21.9% year-over-year.
DCPH revenueDCPH salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09